$EDVA

Endovia Health Sciences, Inc.

CIK:0001553788|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Net revenues			$ 4,224	$ 45,200
Cost of goods sold			(2,376)	(51,802)
Gross profit			1,848	(6,602)
Operating expenses:
Contracted services	3,591	201,660	9,828	421,268
Salary and wages	41,903	685,586	339,654	1,511,682
Non-cash share-based compensation	1,107,558	53,859	1,284,530	189,568
Other general and administrative	827,064	548,117	1,309,649	988,511
Sales and marketing	27,250	12,769	44,523	42,663
Total operating expenses	2,007,366	1,501,991	2,988,184	3,153,692
Loss from operations	(2,007,366)	(1,501,991)	(2,986,336)	(3,160,294)
Other income/(expense):
Interest income	6		506
Interest expense	(231,020)	(625,047)	(1,120,475)	(1,262,392)
Other Income/Expense	244,787		295,018	(1,845)
Amortization of debt discount	(13,448)	(674,962)	(26,894)	(1,653,683)
Gain on Extinguishment of debt	38,683	(5,560,482)	38,683	(5,560,482)
Loss on inventory write off	0	0	(30,078)	0
Loss on Asset write off	(11,126)	0	(282,397)	0
Loss on Fair Value of investment	(41,554)	0	(41,554)	0
Change in FV of derivative	12,644	0	8,664	0
Total other income/(expense)	(1,028)	(6,860,491)	(1,158,527)	(8,478,402)
Provision for income taxes	0	0	0	0
Net loss from continuing operations, net of tax	(2,008,394)	(8,362,482)	(4,144,863)	(11,638,696)
Discontinued operations:
Loss from discontinued operations, net of tax	(46,393)	(130,599)	(46,393)	(504,836)
Net (loss) from discontinued operations	(46,393)	(130,599)	(46,393)	(504,836)
Net loss	(2,054,787)	(8,493,081)	(4,191,256)	(12,143,532)
Foreign currency translation loss	2,178	1,168	(21,111)	(45,902)
Total Comprehensive Income (Loss)	$ (2,052,609)	$ (8,491,913)	$ (4,170,145)	$ (12,189,434)
Loss per share - continuing operations, Basic	$ (0.77)	$ (17.88)	$ (2.30)	$ (27.31)
Loss per share - continuing operations, Diluted	(0.77)	(17.88)	(2.30)	(27.31)
Loss per share - discontinued operations, Basic	(0.02)	(0.41)	(0.02)	(0.41)
Loss per share - discontinued operations, Diluted	$ (0.02)	$ (0.41)	$ (0.02)	$ (0.41)
Weighted average number of common shares outstanding - continuing operations, Basic	3,064,905	474,969	2,126,784	446,224
Weighted average number of common shares outstanding - continuing operations, Diluted	3,064,905	474,969	2,126,784	446,224

Consolidated Statement of Cash Flows - USD ($)	6 Months Ended
Consolidated Statement of Cash Flows - USD ($)	Jun. 30, 2026	Jun. 30, 2025
Statement of Cash Flows [Abstract]
Net loss	$ (4,191,256)	$ (12,143,532)
(Income)loss from discontinued operations	46,393	(504,836)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		4,642
Amortization of debt discount	26,894	1,653,683
ROU assets, net	(5,656)	811
Change in FV of Derivative	(8,664)
Shares issued for services		35,000
Non-cash share-based compensation	1,284,530	194,621
Loss on write-off of investment	250,000
Loss on fair value of investment	41,554
Gain/ (Loss) on extinguishment of debt		5,560,482
Changes in working capital items:
Accounts receivable, net	1,432	148,119
Inventory, net	(21,384)	42,072
Prepaid expenses and other current assets	128,816	10,126
Deposits	22,734
Accounts payable and accrued expenses	(382,731)	2,169,807
Accrued interest payable	785,166	460,164
Net cash used in operating activities - continuing operations	(2,022,172)	(1,359,169)
Cash flows from investing activities:
Capital expenditures	12,926
Loss of Disposal/write off	(217,479)
Net cash used in investing activities - continuing operations	(204,553)
Cash flows from financing activities:
Proceeds from issuance of Common stock	2,949,144
Proceeds from issuance of debt		1,081,650
Proceeds from issuance of Preferred stock		651,000
Principal repayment of debt	(740,041)	(280,484)
Net cash provided by financing activities - continuing operations	2,209,103	1,452,166
Cash flows from discontinued operations
Operating cash flows		(45,230)
Investing cash flows
Financing cash flows
Net cash provided by (used in) discontinued operations		(45,230)
Net cash effect of exchange rate changes on cash	(21,111)	(45,900)
Net change in cash and cash equivalents	(38,733)	1,867
Cash and cash equivalents, beginning of year	281,435	15,346
Cash and cash equivalents, end of period	242,702	17,213
Supplemental disclosure of cash flow information:
Cash paid for Interest	71,161	132,441
Supplemental disclosure of non-cash investing and financing activities
Creation of promissory note related to deferred financing costs associated with ELOC proceeds.	540,132
Notes payable and accrued interest converted to common stock (226,770 shares in 2026 & 224,541 shares in 2025)	84,430	1,665,954
Non-cash debt discount in the form of issuance of equity instruments in conjunction with convertible notes		659,958
Series-B Convertible Preferred Stock Issued 126,710 Shares exchanged for $12,670,435 notes payable and accrued interest		16,387,404
Series-C Convertible Preferred Stock Issued 20,000 Shares exchanged for Subscription Receivable		$ 20,000,000

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 242,702	$ 281,435
Accounts receivable, net	14,316	15,748
Prepaid expenses	100,307	208,051
Inventory	54,922	33,538
Other receivables	72,149	93,221
Deferred finance cost	416,011
Total current assets	900,407	631,993
Non-current assets:
Deposits		22,734
Investment in Salt Tequila USA, LLC		250,000
Investment in Avicanna, net	175,925
Right of use assets		48,041
Property and equipment		12,926
Total non-current assets	175,925	333,701
Total assets	1,076,332	965,694
Current liabilities
Accounts payable and accrued expenses	4,091,058	4,810,061
Right of use liability, current portion		50,720
Related party notes payable	389,000	389,000
Dividends payable	1,569,914	831,944
Notes payable, net of discounts	5,997,984	6,225,581
Derivative liability	180,918	189,582
Accrued interest payable	3,076,398	2,282,528
Liabilities of discontinued operations	1,520,105	1,480,712
Total current liabilities	16,825,377	16,260,128
Long-term liabilities:
Notes payable, net of discounts		3,418
Right of use liability – net of current portion		2,976
Total long-term liabilities		6,394
Total liabilities	16,825,377	16,266,522
Stockholders’ equity:
Preferred stock value
Common Stock, $0.001 par, 100,000,000 shares authorized, 4,127,220 shares outstanding at June 30, 2026 and 749,450 shares outstanding at December 31, 2025	4,127	749
Additional paid in capital	171,062,303	166,563,528
Accumulated other comprehensive income / (loss)	12,717	33,828
Accumulated deficit	(186,828,280)	(181,899,055)
Total stockholders’ equity	(15,749,045)	(15,300,828)
Total liabilities and stockholders’ equity	1,076,332	965,694
Series A 1 Preferred Stock [Member]
Stockholders’ equity:
Preferred stock value	1	1
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred stock value	$ 87	$ 122